RU2016107954A - Способы идентификации и прогнозирования риска сердечно-сосудистого события или заболевания, или смертельного исхода, способы оценки тяжести и мониторинга сердечно-сосудистого события или заболевания, способ мониторинга эффективности терапии - Google Patents
Способы идентификации и прогнозирования риска сердечно-сосудистого события или заболевания, или смертельного исхода, способы оценки тяжести и мониторинга сердечно-сосудистого события или заболевания, способ мониторинга эффективности терапии Download PDFInfo
- Publication number
- RU2016107954A RU2016107954A RU2016107954A RU2016107954A RU2016107954A RU 2016107954 A RU2016107954 A RU 2016107954A RU 2016107954 A RU2016107954 A RU 2016107954A RU 2016107954 A RU2016107954 A RU 2016107954A RU 2016107954 A RU2016107954 A RU 2016107954A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- monitoring
- methods
- cardiovascular event
- strem
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 15
- 230000007211 cardiovascular event Effects 0.000 title claims 6
- 201000010099 disease Diseases 0.000 title claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 4
- 238000012544 monitoring process Methods 0.000 title claims 4
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Claims (12)
1. Способ идентификации субъекта с риском наличия или развития сердечно-сосудистого события или заболевания, или смертельного исхода, отличающийся тем, что измеряют уровень sTREM-1 в образце, полученном от субъекта
2. Способ оценки риска наличия или развития сердечно-сосудистого заболевания или события, или смертельного исхода, отличающийся тем, что измеряют уровень sTREM-1 в образце, полученном от субъекта.
3. Способ оценки тяжести сердечно-сосудистого заболевания или события, отличающийся тем, что измеряют уровень sTREM-1 в образце, полученном от субъекта.
4. Способ по любому из пп. 1-3, отличающийся тем, что уровень sTREM-1 сравнивают с контрольной величиной.
5. Способ по п. 4, отличающийся тем, что более высокий уровень sTREM-1 относительно контрольной величины свидетельствует о риске наличия или развития сердечно-сосудистого события или заболевания, или смертельного исхода.
6. Способ по любому из пп. 1-3, отличающийся тем, что образцом является образец крови.
7. Способ по любому из пп. 1-3, отличающийся тем, что указанным сердечнососудистым событием является инфаркт миокарда.
8. Способ по любому из пп. 1-3, отличающийся тем, что указанным сердечнососудистым событием является атеросклероз.
9. Способ мониторинга сердечно-сосудистого заболевания или события, отличающийся тем, что измеряют уровень sTREM-1 в образце, полученном от субъекта.
10. Способ мониторинга эффективности лечения сердечно-сосудистого заболевания или события, отличающийся тем, что измеряют уровень sTREM-1 в образце, полученном от субъекта.
11. Способ по п. 10, отличающийся тем, что уровень sTREM-1 сравнивают с индивидуальной контрольной величиной для данного субъекта.
12. Способ по п. 11, отличающийся тем, что индивидуальная контрольная величина для субъекта представляет собой уровень sTREM-1, измеренный в образце, полученном от субъекта, до начала лечения.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361863987P | 2013-08-09 | 2013-08-09 | |
| US61/863,987 | 2013-08-09 | ||
| EP14153519.5 | 2014-01-31 | ||
| EP14153519.5A EP2835641A1 (en) | 2013-08-09 | 2014-01-31 | Methods and kits for predicting the risk of having a cardiovascular disease or event |
| PCT/EP2014/067120 WO2015018936A1 (en) | 2013-08-09 | 2014-08-08 | Methods and kits for predicting the risk of having a cardiovascular disease or event |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016107954A true RU2016107954A (ru) | 2017-09-14 |
| RU2721690C2 RU2721690C2 (ru) | 2020-05-21 |
Family
ID=50030127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016107954A RU2721690C2 (ru) | 2013-08-09 | 2014-08-08 | Способы идентификации и прогнозирования риска сердечно-сосудистого события или заболевания, или смертельного исхода, способы оценки тяжести и мониторинга сердечно-сосудистого события или заболевания, способ мониторинга эффективности терапии |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10948498B2 (ru) |
| EP (2) | EP2835641A1 (ru) |
| JP (1) | JP6562915B2 (ru) |
| KR (1) | KR102266302B1 (ru) |
| CN (1) | CN105765382B (ru) |
| AU (1) | AU2014304421B2 (ru) |
| BR (1) | BR112016002668B1 (ru) |
| CA (1) | CA2920652C (ru) |
| ES (1) | ES2973810T3 (ru) |
| IL (1) | IL244013B (ru) |
| MX (1) | MX375421B (ru) |
| NZ (1) | NZ716643A (ru) |
| RU (1) | RU2721690C2 (ru) |
| WO (1) | WO2015018936A1 (ru) |
| ZA (1) | ZA201600963B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106053831A (zh) * | 2016-06-05 | 2016-10-26 | 潘时辉 | 一种用于自身免疫病检测的试剂盒 |
| FI127416B (en) * | 2016-09-29 | 2018-05-31 | Oy Medix Biochemica Ab | Cardiovascular risk assessment method |
| KR102257830B1 (ko) * | 2018-12-18 | 2021-05-28 | 연세대학교 산학협력단 | 사망 위험도의 예측 방법 및 이를 이용한 디바이스 |
| KR20220057534A (ko) * | 2019-09-03 | 2022-05-09 | 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 | 심혈관 위험 사건 예측 및 이의 용도 |
| EP4065152A1 (en) * | 2019-11-25 | 2022-10-05 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease |
| CN116507915A (zh) * | 2020-06-05 | 2023-07-28 | 伊诺特伦公司 | 可溶性trem-1作为患有冠状病毒感染的受试者的严重程度或并发症的标志物 |
| US20230273208A1 (en) * | 2020-06-05 | 2023-08-31 | Inotrem | Soluble trem-1 as a marker of severity or complications for a subject suffering from a coronavirus infection |
| KR102724742B1 (ko) | 2020-12-02 | 2024-11-01 | (주)노보메디슨 | 선천적 대사질환 위험도 점수를 이용한 심뇌혈관질환의 위험도 측정 방법 |
| US20240173376A1 (en) | 2021-03-12 | 2024-05-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Trem-1 inhibitors for the treatment of marfan syndrome |
| WO2023061946A1 (en) | 2021-10-11 | 2023-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of trem-1 for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060084082A1 (en) | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| GB0401730D0 (en) * | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
| WO2008088849A2 (en) * | 2007-01-16 | 2008-07-24 | Wyeth | Inflammation treatment, detection and monitoring via trem-1 |
| JP2010534828A (ja) * | 2007-07-23 | 2010-11-11 | ビオエクセル エスピーエー | スクリーニング、療法及び診断 |
| US20120219943A1 (en) * | 2011-02-03 | 2012-08-30 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| HRP20171585T1 (hr) | 2012-02-15 | 2017-12-01 | Novo Nordisk A/S | Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1) |
-
2014
- 2014-01-31 EP EP14153519.5A patent/EP2835641A1/en not_active Withdrawn
- 2014-08-08 EP EP14753046.3A patent/EP3030901B1/en active Active
- 2014-08-08 CA CA2920652A patent/CA2920652C/en active Active
- 2014-08-08 RU RU2016107954A patent/RU2721690C2/ru not_active Application Discontinuation
- 2014-08-08 MX MX2016001719A patent/MX375421B/es active IP Right Grant
- 2014-08-08 US US14/910,715 patent/US10948498B2/en active Active
- 2014-08-08 BR BR112016002668-3A patent/BR112016002668B1/pt active IP Right Grant
- 2014-08-08 JP JP2016532700A patent/JP6562915B2/ja active Active
- 2014-08-08 AU AU2014304421A patent/AU2014304421B2/en active Active
- 2014-08-08 KR KR1020167006316A patent/KR102266302B1/ko active Active
- 2014-08-08 NZ NZ716643A patent/NZ716643A/en unknown
- 2014-08-08 CN CN201480054699.8A patent/CN105765382B/zh active Active
- 2014-08-08 ES ES14753046T patent/ES2973810T3/es active Active
- 2014-08-08 WO PCT/EP2014/067120 patent/WO2015018936A1/en active Application Filing
-
2016
- 2016-02-08 IL IL244013A patent/IL244013B/en active IP Right Grant
- 2016-02-11 ZA ZA2016/00963A patent/ZA201600963B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3030901A1 (en) | 2016-06-15 |
| KR102266302B1 (ko) | 2021-06-18 |
| EP3030901B1 (en) | 2024-01-10 |
| MX375421B (es) | 2025-03-06 |
| AU2014304421B2 (en) | 2020-01-16 |
| ZA201600963B (en) | 2020-05-27 |
| BR112016002668A2 (pt) | 2018-01-30 |
| IL244013A0 (en) | 2016-04-21 |
| CA2920652A1 (en) | 2015-02-12 |
| KR20160046828A (ko) | 2016-04-29 |
| AU2014304421A1 (en) | 2016-02-25 |
| WO2015018936A1 (en) | 2015-02-12 |
| JP6562915B2 (ja) | 2019-08-21 |
| US10948498B2 (en) | 2021-03-16 |
| MX2016001719A (es) | 2016-06-02 |
| EP3030901C0 (en) | 2024-01-10 |
| CN105765382A (zh) | 2016-07-13 |
| NZ716643A (en) | 2020-06-26 |
| CA2920652C (en) | 2023-03-07 |
| EP2835641A1 (en) | 2015-02-11 |
| RU2721690C2 (ru) | 2020-05-21 |
| JP2016527519A (ja) | 2016-09-08 |
| BR112016002668B1 (pt) | 2023-12-12 |
| IL244013B (en) | 2020-01-30 |
| ES2973810T3 (es) | 2024-06-24 |
| CN105765382B (zh) | 2019-09-13 |
| US20160187352A1 (en) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016107954A (ru) | Способы идентификации и прогнозирования риска сердечно-сосудистого события или заболевания, или смертельного исхода, способы оценки тяжести и мониторинга сердечно-сосудистого события или заболевания, способ мониторинга эффективности терапии | |
| EA201590024A1 (ru) | Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток | |
| BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| JP2016500110A5 (ru) | ||
| MX2015015605A (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| EP3410928A4 (en) | DEVICE AND METHOD FOR ASSESSING HEART FAILURES | |
| FR3011393B1 (fr) | Procede et appareil d'evaluation de l'etat de sante d'une batterie lithium | |
| WO2015025187A8 (en) | Method and device for improving prediction and detection of change in a physiological condition | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| BR112014020211A2 (pt) | métodos para analisar uma série ordenada por tempo de medições de um polímero, para estimar a presença, ausência ou quantidade de um polímero alvo, e para determinar uma alteração em um polímero, programa de computador, e, dispositivos de análise e de diagnóstico | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| AR080361A1 (es) | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) | |
| BR112016024143A2 (pt) | tratamento de câncer | |
| BR112017011557A2 (pt) | sistema para determinar o estado imune ou ciclo imune, métodos para determinar o estado imune e/ou ciclo imune, para otimizar uma resposta fisiológica, para melhorar uma resposta fisiológica e para determinar um estado imune ou ciclo imune. | |
| MX377026B (es) | Biomarcadores para la progresión de enfermedades en melanoma. | |
| AR100013A1 (es) | Procedimiento para el monitoreo, cuantificación y evaluación de actividades de pastoreo y rumia realizadas por rumiantes y dispositivo para ejecutarlo | |
| WO2015048804A3 (en) | Protein biomarker and uses thereof | |
| FR2996192B1 (fr) | Procede de determination de l'etat d'usure d'une piece et d'information d'un client | |
| MX384485B (es) | Deteccion temprana de preeclampsia. | |
| EA201691168A1 (ru) | Способы исследования бета-глюкана | |
| EA201891693A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови | |
| TR201906195T4 (tr) | Niemann pıck hastalığının teşhisi için metot. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180607 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20180907 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190117 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20190424 |